首页> 外文期刊>Endocrine journal >The Threshold of Bone Mineral Density for Vertebral Fracture in Female Patients with Glucocorticoid-induced Osteoporosis
【24h】

The Threshold of Bone Mineral Density for Vertebral Fracture in Female Patients with Glucocorticoid-induced Osteoporosis

机译:女性糖皮质激素诱发骨质疏松症患者椎体骨折的骨密度阈值

获取原文
       

摘要

References(37) Cited-By(16) Glucocorticoid (GC)-induced osteoporosis (GIO) is a serious problem for patients taking GC therapy. GC increases risk for fracture. However, there are controversies regarding the threshold of bone mineral density (BMD) in patients with GIO. The present study aimed to examine the relationship between the presence or absence of vertebral fracture and various indices including BMD in 136 female Japanese patients treated with oral GC (102 patients with autoimmune diseases). Moreover, we analyzed the cut-off values of BMD for incidence of vertebral fracture in patients with oral GC use and compared these values with those in control subjects. BMD was measured by dual-energy X-ray absorptiometry of the lumbar spine, femoral neck, and distal one third of radius. We compared various indices between patients taking oral GC with and without vertebral fracture. Age, body height, and body weight were significantly greater, shorter, and lower in the group with vertebral fracture, respectively. As for BMD, age-matched BMD seemed lower in the fracture group, although the differences were significant between both groups only at the femoral neck. Duration of GC treatment was longer in the fracture group. Cut-off values of BMD at lumbar spine, femoral neck, and distal radius were higher in patients with GC treatment compared with those of control group [GC vs control (g/cm2): 0.807 vs 0.716 at lumbar spine; 0.611 vs 0.581 at femoral; 0.592 vs 0.477 at radius]. The sensitivity and specificity were lower in patients with GC treatment compared with those of control group. The present study demonstrated that the thresholds of BMD for vertebral fracture were higher in Japanese female patients with oral GC treatment at any site compared with postmenopausal subjects. The factors other than BMD were considered to affect bone strength and vertebral fracture risk.
机译:参考文献(37)被引用的By(16)糖皮质激素(GC)诱导的骨质疏松症(GIO)对于接受GC治疗的患者来说是一个严重的问题。 GC增加骨折风险。但是,关于GIO患者的骨矿物质密度(BMD)阈值存在争议。本研究旨在检查136名日本女性口服GC治疗的日本女性患者(102例自身免疫性疾病)中椎骨骨折的存在与否与包括BMD在内的各种指标之间的关系。此外,我们分析了口服GC使用的患者椎骨骨折发生率的BMD临界值,并将其与对照组的值进行了比较。 BMD是通过腰椎,股骨颈和distal骨远端三分之一的双能X射线吸收法测量的。我们比较了口服和不合并椎体骨折患者的各种指标。椎骨骨折组的年龄,身高和体重分别明显更大,更短和更低。至于骨密度,虽然两组之间仅在股骨颈处存在显着差异,但骨折组中年龄匹配的骨密度似乎较低。骨折组的GC治疗时间更长。与对照组相比,接受GC治疗的患者腰椎,股骨颈和远端radius骨的BMD截止值较高[GC vs.对照(g / cm2):0.807 vs. 0.716;股骨分别为0.611和0.581;半径分别为0.592和0.477]。与对照组相比,接受GC治疗的患者的敏感性和特异性较低。本研究表明,与绝经后受试者相比,日本女性在任何部位接受口服GC治疗的女性椎体骨折的BMD阈值均较高。除了骨密度外,其他因素也被认为会影响骨强度和椎骨骨折风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号